KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Accumulated Expenses (2016 - 2025)

Sarepta Therapeutics has reported Accumulated Expenses over the past 16 years, most recently at $359.7 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 294.71% year-over-year to $359.7 million; the TTM value through Dec 2025 reached $359.7 million, up 294.71%, while the annual FY2025 figure was $359.7 million, 294.71% up from the prior year.
  • Accumulated Expenses for Q4 2025 was $359.7 million at Sarepta Therapeutics, up from $31.0 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $383.7 million in Q2 2022 and troughed at $3.2 million in Q3 2021.
  • A 5-year average of $142.9 million and a median of $55.4 million in 2022 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: soared 11496.42% in 2022 and later crashed 98.65% in 2025.
  • Year by year, Accumulated Expenses stood at $271.7 million in 2021, then plummeted by 75.73% to $65.9 million in 2022, then plummeted by 81.7% to $12.1 million in 2023, then surged by 654.92% to $91.1 million in 2024, then skyrocketed by 294.71% to $359.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for SRPT at $359.7 million in Q4 2025, $31.0 million in Q3 2025, and $4.7 million in Q2 2025.